Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104. - Wikidata - awgldk - TriplyDB

Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104.

Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104.

http://www.wikidata.org/entity/Q34644969

about

Novel design principles enable specific targeting of imaging and therapeutic agents to necrotic domains in breast tumors The Flavin Reductase MsuE Is a Novel Nitroreductase that Can Efficiently Activate Two Promising Next-Generation Prodrugs for Gene-Directed Enzyme Prodrug Therapy Mechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate Cancer Hypoxia and Hypoxia-Inducible Factors in Leukemias Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs Tandem mass spectrometry for characterization of covalent adducts of DNA with anticancer therapeutics Sulforaphane Preconditioning Sensitizes Human Colon Cancer Cells towards the Bioreductive Anticancer Prodrug PR-104A Hypoxia-Targeted Drug Q6 Induces G2-M Arrest and Apoptosis via Poisoning Topoisomerase II under Hypoxia Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104 PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma.A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients.PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia.Design, synthesis and biological evaluation of 2H-benzo[b][1,4] oxazine derivatives as hypoxia targeted compounds for cancer therapeutics.Pharmacologically increased tumor hypoxia can be measured by 18F-Fluoroazomycin arabinoside positron emission tomography and enhances tumor response to hypoxic cytotoxin PR-104 Detection of hypoxia in microscopic tumors using 131I-labeled iodo-azomycin galactopyranoside (131I-IAZGP) digital autoradiography.Toward hypoxia-selective DNA-alkylating agents built by grafting nitrogen mustards onto the bioreductively activated, hypoxia-selective DNA-oxidizing agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine).Targeting hypoxic tumour cells to overcome metastasis.AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia KRAS driven expression signature has prognostic power superior to mutation status in non-small cell lung cancer.Evaluation of the efficacy of radiation-modifying compounds using γH2AX as a molecular marker of DNA double-strand breaks Crystal structure of N-(quinolin-6-yl)hydroxyl-amine.Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program.Modulation of the tumor vasculature and oxygenation to improve therapy Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma.New developments in radiation therapy for head and neck cancer: intensity-modulated radiation therapy and hypoxia targeting.Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer.Optimized clostridium-directed enzyme prodrug therapy improves the antitumor activity of the novel DNA cross-linking agent PR-104.The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104.Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222.Zinc finger nuclease knock-out of NADPH:cytochrome P450 oxidoreductase (POR) in human tumor cell lines demonstrates that hypoxia-activated prodrugs differ in POR dependence.Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies.Screening for DNA Alkylation Mono and Cross-Linked Adducts with a Comprehensive LC-MS(3) Adductomic Approach Radiosensitising agents for the radiotherapy of cancer: advances in traditional and hypoxia targeted radiosensitisers.Hypoxia-activated prodrugs in cancer therapy: progress to the clinic.DNA Adduct Profiles Predict in Vitro Cell Viability after Treatment with the Experimental Anticancer Prodrug PR104A.Enzymatic conversion of 6-nitroquinoline to the fluorophore 6-aminoquinoline selectively under hypoxic conditions.DNA Adducts from Anticancer Drugs as Candidate Predictive Markers for Precision Medicine.Drugs in preclinical and early-stage clinical development for pancreatic cancer.Cytochrome P450-activated prodrugs.

P2860

Q22000766-33E608B4-8D49-4786-9E27-FF87D8F15753 Q24609522-AF3535DF-0D95-465B-8D3E-000B1B7CAF2C Q26766638-D51249D6-3B26-4D02-8D6B-7197FF6DF4B8 Q26767167-75E713BD-1223-4CC8-BA20-04FDC98DA921 Q26774750-7902D669-6965-4C8A-B98B-2685944DABCF Q28486298-215F6FD0-2FDA-4855-857D-B678E2BB2598 Q28550585-4BF85ABE-A3C2-4310-8F2A-B271B6877767 Q28551450-54BD66E1-6586-4693-9078-D17C6831FC6A Q28741513-F0E8E93D-1907-4B28-916A-B53F32F63711 Q33395400-69CABD07-0575-4F52-A208-389E54B47753 Q33397528-47FDEBC9-F94B-4428-B554-2F12F07CF39C Q33404024-28DE7D3C-B8B3-49B3-B311-A68D72BA9CFB Q33420436-0EE0B165-6E5A-4F6F-9B6C-6D522A50F515 Q33465375-F820331A-84C4-4741-BD0D-D069529B473B Q33605118-AB4E7100-D605-4569-B7FA-F0C2662E5012 Q33936624-1A599B4F-E481-49A9-A289-CA2F558A2643 Q34061361-F9DCF089-5DF8-4252-A6AE-CE1BACB863A2 Q34086671-B25ABF0F-945A-4419-A01B-0A523E5D694B Q34482552-4F7556A4-7F93-4FB9-9352-4E1757B32A1F Q34544971-3E04A07B-F698-4525-BEF6-418740E4ADB6 Q34567095-74155045-3FFC-4823-968F-1CEC86E73DDA Q34638501-6B1FDBA8-34AE-4740-B903-8F2B41B8B79A Q35005290-C5218CED-30CC-4235-AEFF-A271C9F1DD83 Q35920685-D1A9A6C6-D5A5-4B03-A679-C60B6E5757D9 Q36212847-9CDDF3A5-9A62-46BC-8A00-8A7BD711C568 Q36807138-4D6DB8FB-01AD-4DFC-BF3A-08FC5C4C4F82 Q36938779-468D89AC-A493-4B5C-B853-C5884F62B076 Q37001301-41A3A3A6-8267-4474-B8BD-A3496C5034F5 Q37217739-B76CBA5A-29F4-470A-87AE-CB8988CEE5B1 Q37242284-1D99176A-5E66-4A05-A7BF-D413BF9B3E38 Q37415654-6C9188D2-731F-4D7A-88C3-B40D36129E1B Q37426436-6E4B48C0-1D47-48E4-8F7E-5EA02E5D34E8 Q37450078-5A11CF43-1CBA-48D4-AD95-95BC1E88607E Q37481367-934C8A83-CE4D-4CBA-94A7-2920D80841E8 Q37707385-898E0FB6-4B14-4EBC-850F-43A2322168FC Q37717094-27722F68-7DB5-48B9-B4E2-25F23DBECA9A Q37730301-51649689-C49F-4BAB-809C-D4EF226AF1BF Q37736567-5191ED3F-029D-492C-A80A-A12606E9CE99 Q37973133-471AF7C7-1FD8-4517-986F-779B136585BB Q38077550-30E0AFEE-3C27-4574-A2C0-99AF664294F4

P2860

Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104.

http://www.wikidata.org/entity/Q34644969

description

2007 nî lūn-bûn

@nan

2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Mechanism of action and precli ...... NA cross-linking agent PR-104.

@ast

Mechanism of action and precli ...... NA cross-linking agent PR-104.

@en

Mechanism of action and precli ...... NA cross-linking agent PR-104.

@nl

type

label

Mechanism of action and precli ...... NA cross-linking agent PR-104.

@ast

Mechanism of action and precli ...... NA cross-linking agent PR-104.

@en

Mechanism of action and precli ...... NA cross-linking agent PR-104.

@nl

prefLabel

Mechanism of action and precli ...... NA cross-linking agent PR-104.

@ast

Mechanism of action and precli ...... NA cross-linking agent PR-104.

@en

Mechanism of action and precli ...... NA cross-linking agent PR-104.

@nl

P1433

Q34644969-84DE0FF2-8B01-4045-B89A-BAB38C9A9757

P1476

Q34644969-45800A4D-C367-4237-8BD3-75F2F118B42D

P2093

Q34644969-0A6CAFFF-3803-4130-8125-160E0CE3261A

Q34644969-14303237-AF69-4039-BEBC-84B5360F9B40

Q34644969-1BEB53F9-9194-498D-A67A-6D549E3A796D

Q34644969-2725F522-1894-467F-B167-100B1626A685

Q34644969-2FE6CED2-F2A3-4006-808A-1108B6D942A0

Q34644969-3FFFFBA0-6016-49B9-A5BE-0A0F99FF3153

Q34644969-6D2E3AB3-A23E-4DDE-BA33-24BACF2E6F71

Q34644969-B2E2293B-0FF9-44AE-B8E3-831B7DC2D914

Q34644969-B3545A4B-BE69-45C7-8BA0-ECD58BF55496

Q34644969-B68251D0-8439-47B9-9E04-37EEA5F37366

P304

Q34644969-3731B147-E55F-4098-A6A0-E3AFCCE1861F

P31

Q34644969-213C88FF-A4B4-4DFA-9495-9118D3232453

P356

Q34644969-3C3370B7-B25D-46AD-9F72-AEF83C98DA68

P407

Q34644969-FF38D332-05D0-4BF2-8F22-CFE99FE4A8CF

P433

Q34644969-03F8CF71-D5C4-48A6-AE10-54504F5AA245

P478

Q34644969-D5A4A1F5-E303-4229-B3A6-235E17C74171

P577

Q34644969-46215553-0B60-4EC7-9203-3DB07675CEFF

P5875

Q34644969-790372EB-AD61-4E7B-8062-AE31D1F98E55

P698

Q34644969-E7BE52B1-D1CF-4823-AA5D-5CEB7D065224

P921

Q34644969-2BC98FC6-0821-436C-954B-F4C2229CD428

P356

1078-0432.CCR-07-0478

P1433

Clinical Cancer Research

P1476

Mechanism of action and precli ...... NA cross-linking agent PR-104.

@en

P2093

Adam V Patterson

http://www.w3.org/2001/XMLSchema#string

Dianne M Ferry

http://www.w3.org/2001/XMLSchema#string

Graham J Atwell

http://www.w3.org/2001/XMLSchema#string

Kashyap Patel

http://www.w3.org/2001/XMLSchema#string

Kevin O Hicks

http://www.w3.org/2001/XMLSchema#string

Rachelle S Singleton

http://www.w3.org/2001/XMLSchema#string

Shangjin Yang

http://www.w3.org/2001/XMLSchema#string

Shelley J Edmunds

http://www.w3.org/2001/XMLSchema#string

Sophie P Syddall

http://www.w3.org/2001/XMLSchema#string

Susan M Pullen

http://www.w3.org/2001/XMLSchema#string

P304

3922-3932

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-07-0478

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2007-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6230479

http://www.w3.org/2001/XMLSchema#string

P698

17606726

http://www.w3.org/2001/XMLSchema#string

P921